Drug targeting to the brain : transfer of picolinic acid along the olfactory pathways
Picolinic acid (PA) protects against quinolinic acid- and kainic acid-induced neurotoxicity in the brain. To study the uptake of PA to the brain, we administered [3H]PA via a unilateral nasal instillation or iv injection to mice. Autoradiography demonstrated a rapid uptake of radioactivity in the olfactory nerve layer and in the ipsilateral olfactory bulb (OB) following nasal instillation of [3H]PA. After 4 h, there was a high level of radioactivity in the central parts of the ipsilateral OB and olfactory peduncle. Moreover, iv injection of [3H]PA demonstrated a selective uptake and retention of radioactivity in the OB. Gas chromatography-mass spectrometry (GC-MS) demonstrated the presence of PA and PA-glycine conjugate in the OB. In mice with reduced peripheral olfactory innervations there was a decreased uptake of [3H]PA in the OB as compared to controls suggesting that an intact olfactory neuroepithelium is a prerequisite for an uptake of PA to the OB. There is an increased interest in brain targeting of drugs with limited ability to pass the blood-brain barrier. The present results demonstrate that PA fulfils structural requirements for a transfer along the olfactory pathways to the brain.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2002 |
---|---|
Erschienen: |
2002 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Journal of drug targeting - 10(2002), 6 vom: 28. Sept., Seite 469-78 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bergström, U [VerfasserIn] |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 16.04.2003 Date Revised 06.11.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM123531845 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM123531845 | ||
003 | DE-627 | ||
005 | 20231222201551.0 | ||
007 | tu | ||
008 | 231222s2002 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0412.xml |
035 | |a (DE-627)NLM123531845 | ||
035 | |a (NLM)12575737 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bergström, U |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug targeting to the brain |b transfer of picolinic acid along the olfactory pathways |
264 | 1 | |c 2002 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 16.04.2003 | ||
500 | |a Date Revised 06.11.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Picolinic acid (PA) protects against quinolinic acid- and kainic acid-induced neurotoxicity in the brain. To study the uptake of PA to the brain, we administered [3H]PA via a unilateral nasal instillation or iv injection to mice. Autoradiography demonstrated a rapid uptake of radioactivity in the olfactory nerve layer and in the ipsilateral olfactory bulb (OB) following nasal instillation of [3H]PA. After 4 h, there was a high level of radioactivity in the central parts of the ipsilateral OB and olfactory peduncle. Moreover, iv injection of [3H]PA demonstrated a selective uptake and retention of radioactivity in the OB. Gas chromatography-mass spectrometry (GC-MS) demonstrated the presence of PA and PA-glycine conjugate in the OB. In mice with reduced peripheral olfactory innervations there was a decreased uptake of [3H]PA in the OB as compared to controls suggesting that an intact olfactory neuroepithelium is a prerequisite for an uptake of PA to the OB. There is an increased interest in brain targeting of drugs with limited ability to pass the blood-brain barrier. The present results demonstrate that PA fulfils structural requirements for a transfer along the olfactory pathways to the brain | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Picolinic Acids |2 NLM | |
650 | 7 | |a picolinic acid |2 NLM | |
650 | 7 | |a QZV2W997JQ |2 NLM | |
700 | 1 | |a Franzén, A |e verfasserin |4 aut | |
700 | 1 | |a Eriksson, C |e verfasserin |4 aut | |
700 | 1 | |a Lindh, C |e verfasserin |4 aut | |
700 | 1 | |a Brittebo, E B |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 10(2002), 6 vom: 28. Sept., Seite 469-78 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2002 |g number:6 |g day:28 |g month:09 |g pages:469-78 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2002 |e 6 |b 28 |c 09 |h 469-78 |